ES2082959T3 - Procedimiento para desarrollar la sintesis de una droga contraceptiva y de control del ciclo menstrual que tiene propiedades anticinetosicas, oncostaticas y terapeuticas para el tratamiento de los tumores de mama y melanomas. - Google Patents

Procedimiento para desarrollar la sintesis de una droga contraceptiva y de control del ciclo menstrual que tiene propiedades anticinetosicas, oncostaticas y terapeuticas para el tratamiento de los tumores de mama y melanomas.

Info

Publication number
ES2082959T3
ES2082959T3 ES91830402T ES91830402T ES2082959T3 ES 2082959 T3 ES2082959 T3 ES 2082959T3 ES 91830402 T ES91830402 T ES 91830402T ES 91830402 T ES91830402 T ES 91830402T ES 2082959 T3 ES2082959 T3 ES 2082959T3
Authority
ES
Spain
Prior art keywords
dose
bromomelatonin
iodomelatonin
per day
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91830402T
Other languages
English (en)
Inventor
Franco Fraschini
Ermanno Duranti
Bella Luigi Di
Bojidar Stankov
Aldo Laguzzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
I F L O S A S Di Giorgio E Ald
Original Assignee
I F L O S A S Di Giorgio E Ald
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT02159690A external-priority patent/IT1243978B/it
Priority claimed from IT2233890A external-priority patent/IT1251743B/it
Priority claimed from ITMI912438A external-priority patent/IT1251204B/it
Application filed by I F L O S A S Di Giorgio E Ald filed Critical I F L O S A S Di Giorgio E Ald
Application granted granted Critical
Publication of ES2082959T3 publication Critical patent/ES2082959T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

ESTA INVENCION DESCRIBE UN MEDICAMENTO PARA USO HUMANO, TENIENDO PROPIEDADES CONTROLADORAS DEL CICLO MENSTRUAL Y ANTICONCEPTIVAS, CARACTERIZADO PORQUE DICHO MEDICAMENTO COMPRENDE N-ACETIL -5-METOXITRIPTAMINA O NELATONINA EN UNA DOSIS DE 100-200 MG POR UNIDAD N-ACETIL-2-BROMO-5-METOXITRIPTAMINA O -BROMO-MELATONINA EN UNA DOSIS DE 25-50 MGR POR UNIDAD N-ACETIL-2-YODO-5-METOXITRIPTAMINA O 2-YODOMELATONINA, EN UNA DOSIS DE 20-40 MG POR UNIDAD, EN ASOCIACION CON UN COMPUESTO PROGESTAGENO. LA ADMINISTRACION SE LLEVA A CABO DURANTE 23 DIAS, UTILIZANDO UNA ASOCIACION DE 2-RODOMELATONINA Y/O MELATONINA Y/O 2-BROMOMELATONINA Y UN COMPUESTO PROGESTINICO, SEGUIDO DE 5 DIAS EN LOS QUE SE ADMINISTRA SOLAMENTE 2-YODOMELATONINA Y/O MELATONINA Y/O 2-BROMOMELATONINA; EL MEDICAMENTO TIENE PROPIEDADES ONCOSTATICAS PREVENTIVAS Y TERAPEUTICAS EN TUMORES MAMARIOS Y MELANOMAS, CARACTERIZADO POR EL USO DE 2-YODOMELATONINA, MELATONINA Y 2-BROMOMELATONINA RESPECTIVAMENTE CON DOSIS DE 20-40 MG, 100-200 MG, 25-50 MG POR UNIDAD; Y TENIENDO ADEMAS DICHO MEDICAMENTO PROPIEDADES ANTICINETOSICAS, Y CARACTERIZANDOSE POR EL USO DE 2-YODOMELATONINA EN UNA DOSIS POR UNIDAD DE 2,5 MG, MELATONINA EN UNA DOSIS POR UNIDAD DE 10 MG Y 2-BROMOMELATONINA EN UNA DOSIS POR UNIDAD DE 3,5 MG, BIEN INDIVIDUALMENTE Y/O EN ASOCIACION CON LA COENZIMA ACETI-A-(ACCOA), EN UNA DOSIS DE 8-10 MG POR UNIDAD.
ES91830402T 1990-09-28 1991-09-27 Procedimiento para desarrollar la sintesis de una droga contraceptiva y de control del ciclo menstrual que tiene propiedades anticinetosicas, oncostaticas y terapeuticas para el tratamiento de los tumores de mama y melanomas. Expired - Lifetime ES2082959T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT02159690A IT1243978B (it) 1990-09-28 1990-09-28 Farmaco per uso umano, ad azione contraccettiva ed oncostatica preventiva, nei tumori del seno, dell'utero e nel melanoma.
IT2233890A IT1251743B (it) 1990-12-11 1990-12-11 Farmaco per uso umano, ad azione contraccettiva ed oncostatica preventiva e terapeutica, nei tumori del seno, dell'utero e nel melanoma, ad azione anticinetosica a base di agonisti della melatonina ad alta affinita', in associazione con un progestinico
ITMI912438A IT1251204B (it) 1991-09-16 1991-09-16 Farmaco per uso umano, ad azione contraccettiva e regolatrice del ciclo mestruale, ad azione oncostatica preventiva e terapeutica, nei tumori mammari e nel melanoma, e ad azione anticinetosica e metodo di sintesi

Publications (1)

Publication Number Publication Date
ES2082959T3 true ES2082959T3 (es) 1996-04-01

Family

ID=27273202

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91830402T Expired - Lifetime ES2082959T3 (es) 1990-09-28 1991-09-27 Procedimiento para desarrollar la sintesis de una droga contraceptiva y de control del ciclo menstrual que tiene propiedades anticinetosicas, oncostaticas y terapeuticas para el tratamiento de los tumores de mama y melanomas.

Country Status (8)

Country Link
US (1) US5272141A (es)
EP (2) EP0641565B1 (es)
JP (1) JP2849692B2 (es)
AT (2) ATE131058T1 (es)
DE (2) DE69115221T2 (es)
DK (1) DK0483077T3 (es)
ES (1) ES2082959T3 (es)
GR (1) GR3019175T3 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1254995B (it) * 1992-06-24 1995-10-11 Farmaco contenente melatonina e/o agonisti, con somministrazione particolarmente efficace nelle patologie che interferiscono con i ritmi circandiani
IT1255199B (it) * 1992-07-01 1995-10-20 Franco Fraschini Farmaco sintetizzato analogo della melatonina particolarmente efficacenelle patologie che interferiscono con i ritmi circadiani
AU2109695A (en) 1994-03-30 1995-10-23 Novartis Ag Screening method using the rzr receptor family
US6403631B1 (en) 1995-11-24 2002-06-11 Equitech Laboratories, Inc. Method and compositions for enhancing pregnancy success in an animal
US5792785A (en) * 1995-11-24 1998-08-11 Equitech Laboratories, Inc. Method for enhancing pregnancy success in an animal
US6133453A (en) * 1998-05-15 2000-10-17 Pharm-Eco Laboratories, Inc. Method for making substituted indoles
US6417214B1 (en) 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6423699B1 (en) 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
US6380178B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Cyclic regimens using cyclocarbamate and cyclic amide derivatives
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6358947B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6399593B1 (en) 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6319912B1 (en) 1999-05-04 2001-11-20 American Home Products Corporation Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
WO2005084664A1 (ja) * 2004-03-08 2005-09-15 Kanazawa University Technology Licensing Organization Ltd. インドール誘導体及びその用途
JP3964417B2 (ja) * 2004-09-27 2007-08-22 国立大学法人金沢大学 インドール誘導体を有効成分とするα２受容体遮断剤及び血管拡張剤
CN113480467B (zh) * 2021-07-13 2022-12-30 河北维达康生物科技有限公司 一种放射性示踪剂2-碘褪黑素的合成工艺
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3920664A (en) * 1972-07-21 1975-11-18 Lilly Co Eli D-2-halo-6-alkyl-8-substituted ergolines and related compounds
US4166182A (en) * 1978-02-08 1979-08-28 Eli Lilly And Company 6-n-propyl-8-methoxymethyl or methylmercaptomethylergolines and related compounds
JPS5686130A (en) * 1979-12-18 1981-07-13 Nissan Chem Ind Ltd Alpha-halo m-benzoylphenyl acetic acid derivative
JPS6033820A (ja) * 1983-08-05 1985-02-21 Nippon Steel Corp 加熱手段を備えた熱間鋼材蓄積装置
US4614807A (en) * 1984-10-04 1986-09-30 Eli Lilly And Company 6,7-dihalomelatonins
JPS6256475A (ja) * 1985-09-05 1987-03-12 Daicel Chem Ind Ltd ５−ハロピリジン−３−カルボキサミド化合物
US4855305A (en) * 1987-03-23 1989-08-08 Applied Medical Research Compositions and methods of effecting contraception utilizing melatonin
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico

Also Published As

Publication number Publication date
DE69115221D1 (de) 1996-01-18
EP0641565B1 (en) 2000-03-15
ATE190490T1 (de) 2000-04-15
US5272141A (en) 1993-12-21
JPH06263635A (ja) 1994-09-20
DK0483077T3 (da) 1996-04-15
EP0483077B1 (en) 1995-12-06
DE69115221T2 (de) 1996-08-22
EP0483077A3 (en) 1992-09-23
ATE131058T1 (de) 1995-12-15
EP0641565A1 (en) 1995-03-08
JP2849692B2 (ja) 1999-01-20
GR3019175T3 (en) 1996-06-30
EP0483077A2 (en) 1992-04-29
DE69132061D1 (de) 2000-04-20

Similar Documents

Publication Publication Date Title
ES2082959T3 (es) Procedimiento para desarrollar la sintesis de una droga contraceptiva y de control del ciclo menstrual que tiene propiedades anticinetosicas, oncostaticas y terapeuticas para el tratamiento de los tumores de mama y melanomas.
PT90049A (pt) Forma de dosagem para administrar um medicamento para terapia humana
NO306377B1 (no) Doseform for avgivelse av et medikament
BR0115162A (pt) Tratamentos antitumorais eficazes
ES2067231T3 (es) Formas de dosificado para suministrar un agente antiparkinson.
FI920956A0 (fi) Doseringsform foer administrering av oral hypoglykemisk glipisid.
KR920019342A (ko) 골질환 치료제
DE3382641T2 (de) Arzneimittel fuer die therapeutische behandlung von alopezie.
ES2141109T3 (es) Procedimiento para la prevencion de la reestenosis despues de la reconfiguracion de los vasos del organismo.
AR011133A1 (es) MICROGRÁNULOS DE LIBERACIoN CONTROLADA QUE CONTIENEN CISPLATINO , PROCEDIMIENTO DE SU PREPARACIoN, COMPOSICIoN FARMACÉUTICA Y UTILIZACIoN EN LA FABRICACIoN DE UN MEDICAMENTO POLIQUIMIOTERAPIA O EN ASOCIACIoN CON UNA RADIOTERAPIA.
DE69327432T2 (de) Heilmittel für wunden und hämorrhoiden
ES2033021T3 (es) Agente con efecto destructivo a tumores malignos, procedimiento para su obtencion y preparacion para la aplicacion en la terapia de enfermos de cancer.
BR112023006337A2 (pt) Produto farmacêutico, uso de um conjugado anticorpo anti-her2-fármaco ou um inibidor seletivo de parp1, e, método de tratamento do câncer
AR043071A1 (es) Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica
ES2135342B1 (es) Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama.
ES2037808T3 (es) Procedimiento para la obtencion de medicamentos para la profilaxis y terapia de enfermedades producidas por retrovirus.
ES2094834T3 (es) Dispositivo para el lavado, para finalidades terapeuticas o de higiene, de conductos internos humanos o animales.
KR950013513A (ko) 약제 제조용 모에노마이신 및 이의 유도체, 및 모에노마이신 또는 이의 유도체를 함유하는 약제
MX9303023A (es) Composicion farmaceutica para tratar desordenes gastricos.
MX9203361A (es) Composiciones farmaceuticas que contienen cloruro de galio.
SE8102161L (sv) "3,7,11,15-tetrametyl-2,4,6,10,14-hexadekapentaensyra
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
FR2392668A1 (fr) Medicament a base de coproporphyrine
KR930702016A (ko) 골다공증 치료제
DE69840451D1 (de) Interferon-immuntherapie mit niedriger dosis

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 483077

Country of ref document: ES